| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
![N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺](http://www.invivochem.com/upload/0201/CgAGS11mfb-ATNqLAAAudzJVf1k495.png)
|
V0050 | TG-101209 | 936091-14-4 | TG101209 is a novel, potent, orally bioactive and selective small molecule JAK2 inhibitor with IC50 of 6 nM. |
|
V0048 | Regorafenib (BAY73-4506) | 755037-03-7 | Regorafenib (also known as BAY 73-4506; BAY-73-4506) is a potent andorally bioavailable multi-kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. |
|
V0071 | Regorafenib HCl (BAY-73-4506) | 835621-07-3 | Regorafenib HCl, the hydrochloric acid salt of regorafenib (also known as BAY 73-4506), is a potent inhibitor of multi-kinase including VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. |
|
V0072 | Regorafenib monohydrate (BAY73-4506) | 1019206-88-2 | Regorafenib monohydrate(also known as BAY 73-4506 monohydrate), the hydrated form ofRegorafenib, is an orally bioavailable multi-kinase inhibitor targeting kinases such as VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
